Article: Rotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
AuthorsPhua, KB1
Lim, FS4
Lau, YL2
Nelson, EAS9
Huang, LM5
Quak, SH6
Lee, BW7
Doorn, LJV8
Teoh, YL3 4
Tang, H3
Suryakiran, PV3
Smolenov, IV3
Bock, HL3
Han, HH3
Keywords3Years
Efficacy
Gastroenteritis
Rix4414
Rotavirus
Issue Date2012
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
CitationVaccine, 2012, v. 30 n. 30, p. 4552-4557 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2012.03.030
AbstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
ISSN0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
DOIhttp://dx.doi.org/10.1016/j.vaccine.2012.03.030
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorPhua, KB
dc.contributor.authorLim, FS
dc.contributor.authorLau, YL
dc.contributor.authorNelson, EAS
dc.contributor.authorHuang, LM
dc.contributor.authorQuak, SH
dc.contributor.authorLee, BW
dc.contributor.authorDoorn, LJV
dc.contributor.authorTeoh, YL
dc.contributor.authorTang, H
dc.contributor.authorSuryakiran, PV
dc.contributor.authorSmolenov, IV
dc.contributor.authorBock, HL
dc.contributor.authorHan, HH
dc.date.accessioned2012-10-30T06:09:11Z
dc.date.available2012-10-30T06:09:11Z
dc.date.issued2012
dc.description.abstractRIX4414 (Rotarix™), has shown high efficacy during the first 2-years of life. A 2-year randomized, double-blind, placebo-controlled trial in Singapore, Hong Kong, and Taiwan was extended for another year. Infants (6-17. weeks) received 2-doses (1-2. months apart) of RIX4414 (n= 5359) or placebo (n= 5349). During the third-year follow-up, 4359 (RIX4414) and 4328 (placebo) infants were monitored. 64 (1.2%) and 2 (0.04%) infants in the placebo and RIX4414 groups, respectively, reported severe rotavirus-gastroenteritis (RVGE), resulting in a vaccine efficacy of 96.9% (95% CI [88.3-99.6]). Efficacy was 100% (67.5-100) in the third-year. RIX4414 was efficacious against G1 (100.0% [84.8-100]) and pooled non-G1 RV types (94.9% [80.2-99.4]). This study shows that the vaccine is highly efficacious, regardless of circulating RV-types, up to the first 3. years of life in affluent Asian urban populations. © 2012 Elsevier Ltd.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationVaccine, 2012, v. 30 n. 30, p. 4552-4557 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.vaccine.2012.03.030
dc.identifier.citeulike10784864
dc.identifier.doihttp://dx.doi.org/10.1016/j.vaccine.2012.03.030
dc.identifier.epage4557
dc.identifier.issn0264-410X
2011 Impact Factor: 3.766
2011 SCImago Journal Rankings: 0.369
dc.identifier.issue30
dc.identifier.scopuseid_2-s2.0-84862020627
dc.identifier.spage4552
dc.identifier.urihttp://hdl.handle.net/10722/170465
dc.identifier.volume30
dc.languageeng
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
dc.publisher.placeUnited Kingdom
dc.relation.ispartofVaccine
dc.relation.referencesReferences in Scopus
dc.subject3Years
dc.subjectEfficacy
dc.subjectGastroenteritis
dc.subjectRix4414
dc.subjectRotavirus
dc.titleRotavirus vaccine RIX4414 efficacy sustained during the third year of life: A randomized clinical trial in an Asian population
dc.typeArticle
Author Affiliations
  1. KK Women's And Children's Hospital
  2. The University of Hong Kong
  3. GlaxoSmithKline
  4. National Healthcare Group Polyclinics, Singapore
  5. National Taiwan University Hospital
  6. National University of Singapore
  7. Mount Elizabeth Medical Centre
  8. Delft Diagnostic Laboratory
  9. Chinese University of Hong Kong